Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;61(2):240-245.
doi: 10.1016/j.amepre.2021.02.004. Epub 2021 Apr 29.

Past-Year Kratom Use in the U.S.: Estimates From a Nationally Representative Sample

Affiliations

Past-Year Kratom Use in the U.S.: Estimates From a Nationally Representative Sample

Joseph J Palamar. Am J Prev Med. 2021 Aug.

Abstract

Introduction: Kratom is a plant with partial opioid agonist effects, and its use has become popular to ameliorate symptoms of opioid withdrawal. However, use has been linked to thousands of poisonings, although most have involved use of other drugs. Little is known regarding prevalence and correlates of use in the general U.S.

Methods: Data were examined from the 2019 National Survey on Drug Use and Health, a nationally representative probability sample of non-institutionalized individuals aged ≥12 years in the U.S. (N=56,136). Prevalence and correlates of past-year kratom use were estimated. Data were analyzed in 2020.

Results: An estimated 0.7% (95% CI=0.6, 0.8) of individuals in the U.S. have used kratom in the past year. Past-year proxy diagnosis of prescription opioid use disorder was associated with increased odds for kratom use (AOR=3.20, 95% CI=1.38, 7.41), with 10.4% (95% CI=6.7, 15.9) of those with use disorder reporting use. Opioid misuse not accompanied with use disorder was not associated with kratom use. Those reporting past-year cannabis use both with (AOR=4.33, 95% CI=2.61, 7.19) and without (AOR=4.57, 95% CI=3.29, 6.35) use disorder and those reporting past-year cocaine use (AOR=1.69, 95% CI=1.06, 2.69) and prescription stimulant misuse (AOR=2.10, 95% CI=1.44, 3.05) not accompanied with use disorder were at higher odds for kratom use.

Conclusions: Kratom use is particularly prevalent among those with prescription opioid use disorder, but it is also prevalent among people who use other drugs. Research is needed to determine reasons for use and potential dangers associated with adding kratom to drug repertoires.

PubMed Disclaimer

Comment in

References

    1. Adkins JE, Boyer EW, McCurdy CR. Mitragyna speciosa, a psychoactive tree from Southeast Asia with opioid activity. Curr Top Med Chem. 2011;11(9):1165–1175. 10.2174/156802611795371305. - DOI - PubMed
    1. Eggleston W, Stoppacher R, Suen K, Marraffa JM, Nelson LS. Kratom use and toxicities in the United States. Pharmacotherapy. 2019;39(7):775–777. 10.1002/phar.2280. - DOI - PubMed
    1. Demick DS, Lee TT, Summers AT, El-Mallakh RS. Kratom: a growing substance of abuse in the United States. Ann Clin Psychiatry. 2020;32(4):275–280. 10.12788/acp.0012. - DOI - PubMed
    1. Babu KM, McCurdy CR, Boyer EW. Opioid receptors and legal highs: salvia divinorum and Kratom. Clin Toxicol. 2008;46(2):146–152. 10.1080/15563650701241795. - DOI - PubMed
    1. Boyer EW, Babu KM, Adkins JE, McCurdy CR, Halpern JH. Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth). Addiction. 2008;103(6):1048–1050. 10.1111/j.1360-0443.2008.02209.x. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances